Immunovaccine jab protects monkeys from anthrax; Tekmira hep B RNAi drug shows promise;

> A University of Nebraska Medical Center researcher has received a 5-year, $3.3 million grant from NIH to study 10 rare diseases that affect children beginning in infancy or early childhood and throughout their life. Release

> Amgen ($AMGN) is looking into ways to ramp up production of ZMapp, an investigational drug developed by San Diego-based Mapp Biopharmaceutical to fight Ebola. More

> Immunovaccine unveiled positive results from a preclinical study, showing that its DepoVax delivery system prevented anthrax infections in monkeys exposed to the bacteria. Release

> Tekmira Pharmaceuticals ($TKMR) rolled out new preclinical data, showing that its RNA interference therapy TKM-HBV was effective in mice against hepatitis B. More

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.